LYVE1 and Burkitt lymphoma: Furthermore, strong immunohistochemical expression of antibody against novel lymphatic marker, LYVE-1 (Figure 3A), might allow discrimination of BL from malignant vascular tumors [15], although it will be intriguing to see whether LYVE-1 immunoexpression pattern have reliable roles in this regard.